Latest Blogs

Sep 16, 2021
Dr. Atlal Abusanad discusses how the underrepresentation of female oncologists in prominent roles is due to a bias in valuing their capability and potential. 
Sep 14, 2021
My colleague and friend Christine McGinn discusses the experience of caregiving for her brother, and the lessons she now brings to her own practice.
Sep 09, 2021
"I think of my fellowship studies as a series of layers—every time I do well at one layer, I am ready to move to the next one," said Dr. Tarek Haykal.
Sep 01, 2021
There has never been a more exciting time to be involved in cancer research, with so much knowledge to support our explorations and so many pressing questions still to answer.
Subscribe to this column

Peter Paul Yu, MD, FASCO, FACP

Peter Paul Yu, MD, FACP, FASCO, is the physician-in-chief at Hartford HealthCare Cancer Institute. He is a past president of ASCO, past chair of the Breakthrough Co-Host Committee, and currently serves on the CancerLinQ Board of Governors, as an associate editor of JCO Clinical Cancer Informatics, and on the JCO Oncology Practice editorial board. Follow Dr. Yu on Twitter @YupOnc.

Disclosure.

Apr 16, 2012
It seems that every nephew or niece of mine who has an engineering degree is busy creating the next killer app for a mobile device. Usually it starts with way cool technology, but comes up short in figuring out why enough users would want it or what a sustainable business model might be. On the...
Mar 11, 2012
In health care, we often find ourselves reacting to events rather than dictating them. Being cast in this undesirable position is often unavoidable when dealing with regulators and federal policy. However, the ability to foresee the need for change and thereby influence the direction of change is a...
Nov 20, 2011
This week the FDA decided to withdraw bevacizumab's indication for treatment of metastatic breast cancer. The earlier indication had been approved under FDA's accelerated approval process wherein final approval was conditional on the generation of confirmatory evidence based on clinical trials.
Nov 06, 2011
Let me start by mentioning 2 things I missed earlier about Day 1 of the ASCO HIT/EHRs Symposium.  In the session on Usability, Karen Bell, Chair of CCHIT, mentioned 3 areas where EHRs may impact malpractice risk; Communications, Documentation and Medical Errors. Each of these has the potential to...
Nov 06, 2011
The November 3rd edition of the NEJM features a Perspective article on drug shortages by Mandy Gatesman and Thomas J Smith (NEJM 365:18 page 163) that address many of the causative issues that underlie this growing national problem.  

Pages